Selank Research & Studies
Part of the full Selank guide - a synthetic tuftsin-analogue heptapeptide reference compound, identity-verified with a COA on every vial.
In brief
The research framing for Selank, as captured in this entry, is confined to in-vitro and preclinical neuro/immuno-signaling. The literature attributed here centers on a single cited gene-expression study together with three defined research areas; no therapeutic or human-use claim is supported by these sources.
The detail
A closer look
01
The cited gene-expression study
The one citation provided for this entry is Volkova, A., et al. (2016), 'Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission and Immunity in the Hippocampus,' published in Frontiers in Pharmacology (DOI: 10.3389/fphar.2016.00031; PMID: 26941643). As its title indicates, this work investigates how Selank affects the expression of genes involved in GABAergic neurotransmission and immunity, and it localizes those effects to the hippocampus. It is the empirical anchor for the entry's statement that, in gene-expression studies, Selank alters transcripts tied to GABAergic signaling and immunity - a transcriptional, mechanism-level readout rather than any behavioral or clinical endpoint.
02
Defined research areas
The entry names three research areas. The first is GABAergic neurotransmission gene-expression models, which aligns directly with the Volkova 2016 hippocampal transcript work. The second is serotonergic and anxiolytic-pathway research, reflecting the reported serotonergic effects of the peptide and locating it within anxiolytic-pathway signaling studies. The third is tuftsin-derived immunomodulation, specifically interferon/cytokine studies, which ties the molecule's immune-signaling investigations back to its tuftsin parent peptide. These three areas circumscribe what the provided sources are described as investigating.
03
Why the tuftsin lineage frames the immunology
The immunomodulation research area is not free-standing: the entry explicitly attributes Selank's activity on interferon and cytokine expression to its tuftsin heritage. Because Selank's core (Thr-Lys-Pro-Arg) is the natural immunopeptide tuftsin, immunology studies treat Selank as a stabilized tuftsin analogue, and the Volkova 2016 study's joint focus on GABAergic and immunity-related transcripts in the hippocampus reflects this dual neuro-immune research interest within a single dataset.
04
Boundaries of the evidence
All characterization in this entry is described as in-vitro and preclinical neuro/immuno-signaling, and the entry states plainly that no therapeutic or human-use claim is made. The supporting facts beyond the Volkova citation are physicochemical reference points - molecular weight attributed to ChemicalBook, the tuftsin-plus-PGP parentage attributed to MedKoo, and the prolyl-endopeptidase-resistance stability feature attributed to the Selank literature. No additional studies, numbers, or identifiers beyond these are part of the provided record.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Selank is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.